found that Rucaparib is safe and effective for patients with metastatic BRCA1/2‐ or PALB2‐mutated pancreatic cancer with a median PFS of 13.1 months (95% CI 4.4–21.8 months) and median OS of 23.5 months (95% CI 20–27 months). Here, BRCA1 is linked to pancreatic neoplasm.